Adage Capital Partners’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.9M Sell
586,607
-1,402,984
-71% -$21M 0.01% 725
2026
Q2
$29M Buy
+1,989,591
New +$35.3M 0.04% 397
2025
Q2
– Sell
-538,000
Closed -$10.4M – 942
2025
Q1
$10.4M Buy
+538,000
New +$10.8M 0.02% 577

Other funds holding SMMT

Adage Capital Partners's SMMT Position: Q3 2026 in Review

Adage Capital Partners reduced its Summit Therapeutics (SMMT) stake by 71% in Q3 2026, selling an estimated $21M and leaving 586,607 shares worth $9.9M. The position accounts for 0.01% of the portfolio, ranked #725.

Adage Capital Partners first reported a position in SMMT in Q1 2025 and has held it in 3 quarters since. The position peaked at $29M in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Adage Capital Partners held 586,607 shares of Summit Therapeutics worth $9.9M as of Q3 2026.
  • Adage Capital Partners sold 1,402,984 Summit Therapeutics shares in Q3 2026, an estimated $21M.
  • Summit Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q3 2026, its #725 holding.
  • Adage Capital Partners first reported a position in Summit Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Adage Capital Partners's Summit Therapeutics position peaked at $29M in Q2 2026.
  • 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.